The Evolving Threat of ESBL, AmpC, and KPC -lactamases - SWACM

More documents

Recommendations

Info

Plasmid-encoded AmpC Challenges Detection False susceptibility Development of carbapenem resistance
Clinical Significance of AmpC for K. pneumoniae Bloodstream Isolates Clinical DHA-1 (inducible) CMY-1 like Extended-spectrum Cephalosporin as definitive therapy Failed CTX/CAZ; improved on carbapenem 4/4 died 1/3 died 6 5 30 day mortality 46% 14.3% DHA-1 (13 pts), CMY (14 pts) Pai et al. AAC 2004 48:3720-28
Page 1: The Evolving Threat of ESBL, AmpC,
Page 4 and 5: Normal Gram-negative
Page 6 and 7: ß-lactamases O CH 2 C NH O N S CH
Page 8 and 9: Old Plasmid-Encoded ß-lactamases T
Page 10 and 11: 3 rd Generation Cephalosporins Cefo
Page 12 and 13: Evolution of ESBLs TEM-3, 4 ......
Page 14 and 15: ESBL-producing Organisms Most Commo
Page 16 and 17: CLSI 2010 (M100-S20) • If laborat
Page 18 and 19: 2010 Breakpoints: Are they sufficie
Page 20: Inoculum Effect: In Vitro Artifact?
Page 23 and 24: -lactams Still Active Carbapenems C
Page 25 and 26: AmpC-mediated Resistance Resistant
Page 27: Plasmid-mediated AmpCs • Klebsiel
Page 31 and 32: Klebsiella pneumoniae 225 Resistant
Page 34 and 35: Carbapenemases Class A (KPC, GES, S
Page 36 and 37: Miami KPC Outbreak • Admission fi
Page 38 and 39: Which MIC do we use? Carbapenem MIC
Page 41: Thanks for your attention!

The Evolving Threat of ESBL, AmpC, and KPC -lactamases - SWACM

Create successful ePaper yourself

Delete template?

Save as template?